Evolving Switch Scene Could Drive Nonprescription Reimbursement – Gottlieb
This article was originally published in The Tan Sheet
Executive Summary
Drug sponsors should work with insurers in advance of nonprescription switches to develop reimbursement plans to benefit consumers, particularly when considering a behind-the-counter switch, former FDA Deputy Commissioner Scott Gottlieb advises
You may also be interested in...
Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
FDA's authority to require behind-the-counter sale and other restrictions for some nonprescription switches is strengthened by risk-management provisions of "FDA Revitalization" bills pending in Congress, according to former FDA Deputy Commissioner Scott Gottlieb
Von Eschenbach Promotes Behind-The-Counter Drug Class
FDA and industry should immediately begin pursuing the development of a regulatory process for a behind-the-counter class of drugs, FDA Commissioner Andrew C. von Eschenbach, M.D., told OTC industry executives March 16
Future OTC Technologies Will Bring Regulatory Challenges – Gottlieb
Technological changes in the OTC drug marketplace will prompt changes in the approval process for nonprescription products, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD